Breaking News Instant updates and real-time market news.

ELGX

Endologix

$1.69

-0.06 (-3.43%)

16:04
10/02/18
10/02
16:04
10/02/18
16:04

Endologix narrows higher FY18 revenue view to $150M-$155M from $145M-$155M

Consensus $149.76M.

  • 02

    Oct

  • 06

    Nov

  • 27

    Nov

ELGX Endologix
$1.69

-0.06 (-3.43%)

01/02/18
JPMS
01/02/18
DOWNGRADE
Target $5
JPMS
Underweight
Endologix downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Michael Weinstein downgraded Endologix to Underweight and cut his price target for the shares to $5 from $6. The outlook for the company continued to "deteriorate" over the course of 2017 as pipeline and regulatory challenges mounted, Weinstein tells investors in a research note. He sees an "uncertain path to profitability" and a "very long" road to recovery for Endologix.
03/20/18
PIPR
03/20/18
NO CHANGE
PIPR
Endologix ENCORE study a positive sign, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien was positive on Endologix's ENCORE study results for its Ovation product, and continues to believe "additional data reads and imminent approvals in the coming years should lift shares higher." O'Brien maintained an Overweight rating on shares, recommending investors with more risk tolerance or a longer time horizon accumulate shares at this point.
08/10/18
PIPR
08/10/18
DOWNGRADE
Target $4.75
PIPR
Neutral
Endologix downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Matt O'Brien downgraded Endologix to Neutral and lowered his price target for the shares to $4.75 from $7. The big news from the company's Q2 results is that management is meaningfully reducing revenue guidance for the year as it moves to revamp the business, O'Brien tells investors in a research note. Changes are a good idea "but the risks here are steep (lingering employee disruption, product safety concerns) compared to the rewards ," the analyst contends. He wants to move to the sidelines and see how the reorganization of the business takes shape.
08/23/18
BTIG
08/23/18
NO CHANGE
Target $4
BTIG
Buy
Endologix price target lowered to $4 from $7 at BTIG
BTIG analyst Sean Lavin lowered his price target on Endologix to $4 to reflect the company's recent "drastic" reduction in FY18 revenue guidance, cuts in salesforce, and delayed clinical timelines. Lavin adds that Endologix's Q2 earnings call was also "completely negative", saying the stock is the "Cleveland Browns of MedTech World", with high potential but propensity for things to go wrong. The analyst keeps his Buy rating on Endologix on valuation, but adds that "investors will need the patience of a Browns' fan to stay involved."

TODAY'S FREE FLY STORIES

07:20
10/19/18
10/19
07:20
10/19/18
07:20
General news
FX Update: The Dollar has been choppy »

FX Update: The Dollar has…

OKE

Oneok

$66.94

-0.07 (-0.10%)

07:19
10/19/18
10/19
07:19
10/19/18
07:19
Upgrade
Oneok rating change  »

Oneok upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

GBT

Global Blood Therapeutics

$38.15

2.37 (6.62%)

07:19
10/19/18
10/19
07:19
10/19/18
07:19
Recommendations
Global Blood Therapeutics analyst commentary  »

FDA may consider…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

YARIY

Yara

$0.00

(0.00%)

07:17
10/19/18
10/19
07:17
10/19/18
07:17
Upgrade
Yara rating change  »

Yara upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOLVY

Volvo

$0.00

(0.00%)

07:17
10/19/18
10/19
07:17
10/19/18
07:17
Periodicals
Volvo CEO says doesn't expect fine from emissions probe, Bloomberg says »

Volvo CEO says emissions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

07:17
10/19/18
10/19
07:17
10/19/18
07:17
Downgrade
Associated Banc-Corp rating change  »

Associated Banc-Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

AXP

American Express

$102.86

-1.53 (-1.47%)

07:16
10/19/18
10/19
07:16
10/19/18
07:16
Recommendations
American Express analyst commentary  »

Oppenheimer remains a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

ECYT

Endocyte

$23.40

7.85 (50.48%)

, NVS

Novartis

$86.24

0.9 (1.05%)

07:16
10/19/18
10/19
07:16
10/19/18
07:16
Downgrade
Endocyte, Novartis rating change  »

Endocyte downgraded to…

ECYT

Endocyte

$23.40

7.85 (50.48%)

NVS

Novartis

$86.24

0.9 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 07

    Nov

07:15
10/19/18
10/19
07:15
10/19/18
07:15
General news
Oil Action: Front-month WTI crude prices are up 0.7% »

Oil Action: Front-month…

AVXL

Anavex

$2.47

0.015 (0.61%)

07:14
10/19/18
10/19
07:14
10/19/18
07:14
Hot Stocks
Anavex receives FDA approval of IND for Phase 2 trial of Anavex 2-73 »

Anavex announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$40.37

-1.29 (-3.10%)

07:14
10/19/18
10/19
07:14
10/19/18
07:14
Downgrade
Harley-Davidson rating change  »

Harley-Davidson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WMT

Walmart

$96.19

-0.37 (-0.38%)

07:13
10/19/18
10/19
07:13
10/19/18
07:13
Recommendations
Walmart analyst commentary  »

Oppenheimer more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 15

    Nov

CTSH

Cognizant

$73.60

-0.4 (-0.54%)

07:13
10/19/18
10/19
07:13
10/19/18
07:13
Recommendations
Cognizant analyst commentary  »

Cognizant risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 30

    Oct

  • 02

    Nov

  • 16

    Nov

QSR

Restaurant Brands

$57.16

0.08 (0.14%)

07:12
10/19/18
10/19
07:12
10/19/18
07:12
Recommendations
Restaurant Brands analyst commentary  »

Restaurant Brands'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

IBKC

Iberiabank

$75.27

-2.65 (-3.40%)

07:11
10/19/18
10/19
07:11
10/19/18
07:11
Hot Stocks
Iberiabank sees FY19 average earning assets $28.6B-$28.9B »

Sees FY19 net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

VLRX

Valeritas

$1.22

-0.04 (-3.17%)

07:10
10/19/18
10/19
07:10
10/19/18
07:10
Hot Stocks
Valeritas announces launch of V-Go in Italy »

Valeritas announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

PGTI

PGT Innovations

$21.93

-0.33 (-1.48%)

07:10
10/19/18
10/19
07:10
10/19/18
07:10
Initiation
PGT Innovations initiated  »

PGT Innovations initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

07:10
10/19/18
10/19
07:10
10/19/18
07:10
General news
Canada retail sales preview »

Canada retail sales…

07:10
10/19/18
10/19
07:10
10/19/18
07:10
General news
Canada CPI preview »

Canada CPI preview:…

MYGN

Myriad Genetics

$44.61

0.18 (0.41%)

07:09
10/19/18
10/19
07:09
10/19/18
07:09
Hot Stocks
Myriad Genetics announces new data on Vectra test for RA treatment »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

KBAL

Kimball International

$15.93

-0.27 (-1.67%)

07:08
10/19/18
10/19
07:08
10/19/18
07:08
Hot Stocks
Kimball International to acquire David Edward for $4.85M »

Kimball, a subsidiary of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VFC

VF Corp.

$87.07

-2.22 (-2.49%)

07:08
10/19/18
10/19
07:08
10/19/18
07:08
Hot Stocks
VF Corp. CEO says Q2 results 'were strong driven by our core brands' »

"VF's second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

PYPL

PayPal

$77.50

-2.61 (-3.26%)

, V

Visa

$139.32

-3.1 (-2.18%)

07:08
10/19/18
10/19
07:08
10/19/18
07:08
Recommendations
PayPal, Visa, MasterCard analyst commentary  »

PayPal price target…

PYPL

PayPal

$77.50

-2.61 (-3.26%)

V

Visa

$139.32

-3.1 (-2.18%)

MA

MasterCard

$203.81

-3.58 (-1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 30

    Oct

  • 13

    Nov

  • 13

    Nov

  • 26

    Nov

  • 29

    Jan

PG

Procter & Gamble

$80.31

-0.8628 (-1.06%)

07:07
10/19/18
10/19
07:07
10/19/18
07:07
Earnings
Procter & Gamble sees FY19 core EPS up 3%-8%, consensus $4.37 »

P&G said it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 03

    Mar

LIVX

LiveXLive Media

$2.95

-0.13 (-4.22%)

07:07
10/19/18
10/19
07:07
10/19/18
07:07
Initiation
LiveXLive Media initiated  »

LiveXLive Media initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.